Nephro Trial Files Throwback Thursday: Dapagliflozin in CKD±T2DM, High Dialysis Dose and High-Flux Membrane in Hemodialysis, and MMF vs. CTX in Lupus Nephritis
Nephro Trial Files Throwback Thursday: Dapagliflozin in CKD±T2DM, High Dialysis Dose and High-Flux Membrane in Hemodialysis, and MMF vs. CTX in Lupus Nephritis
nephrotrialfiles.substack.com
Dapagliflozin in Patients with Chronic Kidney Disease Heerspink HJL et al. NEJM (September 2020) Bottom Line: This randomized controlled trial, with a sample size of 4304 patients with chronic kidney disease, evaluated the efficacy and safety of dapagliflozin (10 mg once daily) compared to placebo. The primary outcome, a composite of a sustained decline in estimated GFR, end-stage kidney disease, or death from renal or cardiovascular causes, occurred in 9.2% of the dapagliflozin group and 14.5% of the placebo group. The hazard ratio for this outcome was 0.61 (95% CI, 0.51 to 0.72; P<0.001). The known safety profile of dapagliflozin was confirmed. The study concluded that dapagliflozin significantly reduced the risk of the primary outcome compared to placebo in patients with chronic kidney disease, regardless of the presence or absence of type 2 diabetes.
Nephro Trial Files Throwback Thursday: Dapagliflozin in CKD±T2DM, High Dialysis Dose and High-Flux Membrane in Hemodialysis, and MMF vs. CTX in Lupus Nephritis
Nephro Trial Files Throwback Thursday…
Nephro Trial Files Throwback Thursday: Dapagliflozin in CKD±T2DM, High Dialysis Dose and High-Flux Membrane in Hemodialysis, and MMF vs. CTX in Lupus Nephritis
Dapagliflozin in Patients with Chronic Kidney Disease Heerspink HJL et al. NEJM (September 2020) Bottom Line: This randomized controlled trial, with a sample size of 4304 patients with chronic kidney disease, evaluated the efficacy and safety of dapagliflozin (10 mg once daily) compared to placebo. The primary outcome, a composite of a sustained decline in estimated GFR, end-stage kidney disease, or death from renal or cardiovascular causes, occurred in 9.2% of the dapagliflozin group and 14.5% of the placebo group. The hazard ratio for this outcome was 0.61 (95% CI, 0.51 to 0.72; P<0.001). The known safety profile of dapagliflozin was confirmed. The study concluded that dapagliflozin significantly reduced the risk of the primary outcome compared to placebo in patients with chronic kidney disease, regardless of the presence or absence of type 2 diabetes.